Semaphorin3a promotes advanced diabetic nephropathy

Pardeep K. Aggarwal, Delma Veron, David Thomas, Dionicio Siegel, Gilbert Moeckel, Michael Kashgarian, Alda Tufro

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The onset of diabetic nephropathy (DN) is highlighted by glomerular filtration barrier abnormalities. Identifying pathogenic factors and targetable pathways driving DN is crucial to developing novel therapies and improving the disease outcome. Semaphorin3a (sema3a) is a guidance protein secreted by podocytes. Excess sema3a disrupts the glomerular filtration barrier. Here, using immunohistochemistry, we show increased podocyte SEMA3A in renal biopsies from patients with advanced DN. Using inducible, podocyte-specific Sema3a gain-of-function (Sema3a(+)) mice made diabetic with streptozotocin, we demonstrate that sema3a is pathogenic in DN. Diabetic Sema3a(+) mice develop massive proteinuria, renal insufficiency, and extensive nodular glomerulosclerosis, mimicking advanced DN in humans. In diabetic mice, Sema3a(+) exacerbates laminin and collagen IV accumulation in Kimmelstiel-Wilson-like glomerular nodules and causes diffuse podocyte foot process effacement and F-actin collapse via nephrin, αvβ3 integrin, and MICAL1 interactions with plexinA1. MICAL1 knockdown and sema3a inhibition render podocytes not susceptible to sema3a-induced shape changes, indicating that MICAL1 mediates sema3a-induced podocyte F-actin collapse. Moreover, sema3a binding inhibition or podocyte-specific plexinA1 deletion markedly ameliorates albuminuria and abrogates renal insufficiency and the diabetic nodular glomerulosclerosis phenotype of diabetic Sema3a(+) mice. Collectively, these findings indicate that excess sema3a promotes severe diabetic nephropathy and identifies novel potential therapeutic targets for DN.

Original languageEnglish (US)
Pages (from-to)1743-1759
Number of pages17
JournalDiabetes
Volume64
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Diabetic Nephropathies
Podocytes
Semaphorin-3A
Glomerular Filtration Barrier
Renal Insufficiency
Actins
Albuminuria
Laminin
Streptozocin
Proteinuria
Integrins
Collagen
Immunohistochemistry
Phenotype
Kidney
Biopsy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Aggarwal, P. K., Veron, D., Thomas, D., Siegel, D., Moeckel, G., Kashgarian, M., & Tufro, A. (2015). Semaphorin3a promotes advanced diabetic nephropathy. Diabetes, 64(5), 1743-1759. https://doi.org/10.2337/db14-0719

Semaphorin3a promotes advanced diabetic nephropathy. / Aggarwal, Pardeep K.; Veron, Delma; Thomas, David; Siegel, Dionicio; Moeckel, Gilbert; Kashgarian, Michael; Tufro, Alda.

In: Diabetes, Vol. 64, No. 5, 01.05.2015, p. 1743-1759.

Research output: Contribution to journalArticle

Aggarwal, PK, Veron, D, Thomas, D, Siegel, D, Moeckel, G, Kashgarian, M & Tufro, A 2015, 'Semaphorin3a promotes advanced diabetic nephropathy', Diabetes, vol. 64, no. 5, pp. 1743-1759. https://doi.org/10.2337/db14-0719
Aggarwal PK, Veron D, Thomas D, Siegel D, Moeckel G, Kashgarian M et al. Semaphorin3a promotes advanced diabetic nephropathy. Diabetes. 2015 May 1;64(5):1743-1759. https://doi.org/10.2337/db14-0719
Aggarwal, Pardeep K. ; Veron, Delma ; Thomas, David ; Siegel, Dionicio ; Moeckel, Gilbert ; Kashgarian, Michael ; Tufro, Alda. / Semaphorin3a promotes advanced diabetic nephropathy. In: Diabetes. 2015 ; Vol. 64, No. 5. pp. 1743-1759.
@article{46b465d5b153460e9ff4c64b401f9f6a,
title = "Semaphorin3a promotes advanced diabetic nephropathy",
abstract = "The onset of diabetic nephropathy (DN) is highlighted by glomerular filtration barrier abnormalities. Identifying pathogenic factors and targetable pathways driving DN is crucial to developing novel therapies and improving the disease outcome. Semaphorin3a (sema3a) is a guidance protein secreted by podocytes. Excess sema3a disrupts the glomerular filtration barrier. Here, using immunohistochemistry, we show increased podocyte SEMA3A in renal biopsies from patients with advanced DN. Using inducible, podocyte-specific Sema3a gain-of-function (Sema3a(+)) mice made diabetic with streptozotocin, we demonstrate that sema3a is pathogenic in DN. Diabetic Sema3a(+) mice develop massive proteinuria, renal insufficiency, and extensive nodular glomerulosclerosis, mimicking advanced DN in humans. In diabetic mice, Sema3a(+) exacerbates laminin and collagen IV accumulation in Kimmelstiel-Wilson-like glomerular nodules and causes diffuse podocyte foot process effacement and F-actin collapse via nephrin, αvβ3 integrin, and MICAL1 interactions with plexinA1. MICAL1 knockdown and sema3a inhibition render podocytes not susceptible to sema3a-induced shape changes, indicating that MICAL1 mediates sema3a-induced podocyte F-actin collapse. Moreover, sema3a binding inhibition or podocyte-specific plexinA1 deletion markedly ameliorates albuminuria and abrogates renal insufficiency and the diabetic nodular glomerulosclerosis phenotype of diabetic Sema3a(+) mice. Collectively, these findings indicate that excess sema3a promotes severe diabetic nephropathy and identifies novel potential therapeutic targets for DN.",
author = "Aggarwal, {Pardeep K.} and Delma Veron and David Thomas and Dionicio Siegel and Gilbert Moeckel and Michael Kashgarian and Alda Tufro",
year = "2015",
month = "5",
day = "1",
doi = "10.2337/db14-0719",
language = "English (US)",
volume = "64",
pages = "1743--1759",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "5",

}

TY - JOUR

T1 - Semaphorin3a promotes advanced diabetic nephropathy

AU - Aggarwal, Pardeep K.

AU - Veron, Delma

AU - Thomas, David

AU - Siegel, Dionicio

AU - Moeckel, Gilbert

AU - Kashgarian, Michael

AU - Tufro, Alda

PY - 2015/5/1

Y1 - 2015/5/1

N2 - The onset of diabetic nephropathy (DN) is highlighted by glomerular filtration barrier abnormalities. Identifying pathogenic factors and targetable pathways driving DN is crucial to developing novel therapies and improving the disease outcome. Semaphorin3a (sema3a) is a guidance protein secreted by podocytes. Excess sema3a disrupts the glomerular filtration barrier. Here, using immunohistochemistry, we show increased podocyte SEMA3A in renal biopsies from patients with advanced DN. Using inducible, podocyte-specific Sema3a gain-of-function (Sema3a(+)) mice made diabetic with streptozotocin, we demonstrate that sema3a is pathogenic in DN. Diabetic Sema3a(+) mice develop massive proteinuria, renal insufficiency, and extensive nodular glomerulosclerosis, mimicking advanced DN in humans. In diabetic mice, Sema3a(+) exacerbates laminin and collagen IV accumulation in Kimmelstiel-Wilson-like glomerular nodules and causes diffuse podocyte foot process effacement and F-actin collapse via nephrin, αvβ3 integrin, and MICAL1 interactions with plexinA1. MICAL1 knockdown and sema3a inhibition render podocytes not susceptible to sema3a-induced shape changes, indicating that MICAL1 mediates sema3a-induced podocyte F-actin collapse. Moreover, sema3a binding inhibition or podocyte-specific plexinA1 deletion markedly ameliorates albuminuria and abrogates renal insufficiency and the diabetic nodular glomerulosclerosis phenotype of diabetic Sema3a(+) mice. Collectively, these findings indicate that excess sema3a promotes severe diabetic nephropathy and identifies novel potential therapeutic targets for DN.

AB - The onset of diabetic nephropathy (DN) is highlighted by glomerular filtration barrier abnormalities. Identifying pathogenic factors and targetable pathways driving DN is crucial to developing novel therapies and improving the disease outcome. Semaphorin3a (sema3a) is a guidance protein secreted by podocytes. Excess sema3a disrupts the glomerular filtration barrier. Here, using immunohistochemistry, we show increased podocyte SEMA3A in renal biopsies from patients with advanced DN. Using inducible, podocyte-specific Sema3a gain-of-function (Sema3a(+)) mice made diabetic with streptozotocin, we demonstrate that sema3a is pathogenic in DN. Diabetic Sema3a(+) mice develop massive proteinuria, renal insufficiency, and extensive nodular glomerulosclerosis, mimicking advanced DN in humans. In diabetic mice, Sema3a(+) exacerbates laminin and collagen IV accumulation in Kimmelstiel-Wilson-like glomerular nodules and causes diffuse podocyte foot process effacement and F-actin collapse via nephrin, αvβ3 integrin, and MICAL1 interactions with plexinA1. MICAL1 knockdown and sema3a inhibition render podocytes not susceptible to sema3a-induced shape changes, indicating that MICAL1 mediates sema3a-induced podocyte F-actin collapse. Moreover, sema3a binding inhibition or podocyte-specific plexinA1 deletion markedly ameliorates albuminuria and abrogates renal insufficiency and the diabetic nodular glomerulosclerosis phenotype of diabetic Sema3a(+) mice. Collectively, these findings indicate that excess sema3a promotes severe diabetic nephropathy and identifies novel potential therapeutic targets for DN.

UR - http://www.scopus.com/inward/record.url?scp=84959207712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959207712&partnerID=8YFLogxK

U2 - 10.2337/db14-0719

DO - 10.2337/db14-0719

M3 - Article

C2 - 25475434

AN - SCOPUS:84959207712

VL - 64

SP - 1743

EP - 1759

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 5

ER -